Vimarsana
Biggest News Aggregation in the World

Page 2 - Dementia Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dementia Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dementia Platform Today - Breaking & Trending Today

Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments - Vimarsana News

Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments

Published: March 15, 2022

- Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023.- Lecanemab collaboration to continue unchanged globally-

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomHaruo NaitoAshleigh KossWalter GilbertCharles WeissmannHeinz SchallerMichel VounatsosKenneth MurrayExchange CommissionEisai Co LtdEisai IncPublic Relations DepartmentBiogen IncChief Executive OfficerSir Kenneth MurrayNobel PrizeHealthy LivesDementia PlatformPrivate Securities Litigation Reform ActMedia Outside
Biogen Inc.: Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments - Vimarsana News

Biogen Inc.: Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments

Published: March 14, 2022

Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023Lecanemab collaboration to continue unchanged globallyLecanemab

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomHaruo NaitoWalter GilbertCharles WeissmannHeinz SchallerMichel VounatsosAshleigh KossMike HenckeKenneth MurrayInvestor Relations DepartmentEisai IncBiogen IncExchange CommissionEisai Co LtdPublic Relations DepartmentChief Executive OfficerSir Kenneth MurrayNobel PrizeHealthy LivesDementia PlatformPrivate Securities Litigation Reform ActMedia Outside
Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting - Vimarsana News

Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting

Published: March 11, 2022

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimer's...

Source: prnewswire.com
Related Topics:
United StatesComunidad Autonoma De CatalunaHaruo NaitoHarald HampelRandall BatemanDennisj SelkoeBart De StrooperIvan CheungSusan LandauMichael IrizarryUniversity College LondonMissionad ProgramPrnewswire Eisai Co LtdLecanemab Clinical Development Including New Subcutaneous FormulationInvestor Relations DepartmentNeurology Business Group At Eisai IncAlzheimer Network Trials Unit Tau NexgenHead Of Global Medical AffairsPublic Relations DepartmentDrug AdministrationEisai IncInternational Conference On AlzheimerDrug DevelopmentEisai Co LtdNeurology Business Group
Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting - Vimarsana News

Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting

Published: March 11, 2022

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimer's...

Source: prnewswire.com
Related Topics:
United StatesComunidad Autonoma De CatalunaHaruo NaitoHarald HampelRandall BatemanDennisj SelkoeBart De StrooperIvan CheungSusan LandauMichael IrizarryUniversity College LondonMissionad ProgramPrnewswire Eisai Co LtdLecanemab Clinical Development Including New Subcutaneous FormulationInvestor Relations DepartmentNeurology Business Group At Eisai IncAlzheimer Network Trials Unit Tau NexgenHead Of Global Medical AffairsPublic Relations DepartmentDrug AdministrationEisai IncInternational Conference On AlzheimerDrug DevelopmentEisai Co LtdNeurology Business Group
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab - Vimarsana News

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

Published: March 4, 2022

TOKYO, Mar 4, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data

Source: finanznachrichten.de
Related Topics:
Walter GilbertCharles WeissmannHeinz SchallerKenneth MurrayNational Institutes Of HealthNational Institute OnMinistry Of HealthDrug AdministrationBiogen IncEisai Co LtdExchange CommissionDevices AgencyAlzheimer Clinical Trial ConsortiumMedical Devices AgencyBiologics License ApplicationAccelerated ApprovalPrior Assessment ConsultationClinical Trial ConsortiumNational InstituteNational InstitutesDisease Assessment Scale CognitiveClinical Dementia RatingMini Mental State ExaminationDementia PlatformSir Kenneth Murray